Zevra Therapeutics (ZVRA) Net Income Growth (1y) (2015 - 2026)
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Net Income Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 82.99% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 95.87% |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | -88.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -88.28% |
| Mar 31, 2026 | 1,322.65% |
| Dec 31, 2025 | 134.04% |
| Sep 30, 2025 | 98.36% |
| Jun 30, 2025 | 474.94% |
| Mar 31, 2025 | 81.36% |
| Dec 31, 2024 | -79.67% |
| Sep 30, 2024 | -220.49% |
| Jun 30, 2024 | -674.39% |
| Mar 31, 2024 | -25.76% |
| Dec 31, 2023 | -445.95% |
| Sep 30, 2023 | -56.70% |
| Jun 30, 2023 | 89.30% |
| Mar 31, 2023 | -609.07% |
| Dec 31, 2022 | 312.73% |
| Sep 30, 2022 | -276.12% |
| Jun 30, 2022 | -487.59% |
| Mar 31, 2022 | 81.90% |
| Dec 31, 2021 | 44.41% |
| Sep 30, 2021 | 41.54% |